David is the Strategy & Innovation Lead in AstraZeneca’s Biopharmaceutical Unit, where he is responsible for driving entrepreneurial activities and identifying game-changing technologies for use across R&D.
A neuroscientist by training, David holds a PhD in Molecular Neuroscience from the University of Cambridge, where he investigated the structure and function of ligand-gated ion channels in both eukaryotic and prokaryotic organisms.
Prior to joining AstraZeneca, David was a strategy consultant for PwC where he advised Life Science companies and public organisations on topics related to R&D strategy, M&A, pricing and market access, and growth strategy. David maintains an active network in Cambridge, London and beyond and interacts with numerous start-ups, particularly within the digital health space. He is also interested in entrepreneurship and understanding how pharma can support innovation.